GB202006390D0 - Novel treatments - Google Patents

Novel treatments

Info

Publication number
GB202006390D0
GB202006390D0 GBGB2006390.5A GB202006390A GB202006390D0 GB 202006390 D0 GB202006390 D0 GB 202006390D0 GB 202006390 A GB202006390 A GB 202006390A GB 202006390 D0 GB202006390 D0 GB 202006390D0
Authority
GB
United Kingdom
Prior art keywords
novel treatments
treatments
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2006390.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aqilion AB
Original Assignee
Aqilion AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aqilion AB filed Critical Aqilion AB
Priority to GBGB2006390.5A priority Critical patent/GB202006390D0/en
Publication of GB202006390D0 publication Critical patent/GB202006390D0/en
Priority to KR1020227041908A priority patent/KR20230024892A/ko
Priority to JP2022566661A priority patent/JP2023524519A/ja
Priority to AU2021266154A priority patent/AU2021266154A1/en
Priority to CA3176994A priority patent/CA3176994A1/en
Priority to JP2022566660A priority patent/JP7702427B2/ja
Priority to CN202180044567.7A priority patent/CN115768429B/zh
Priority to GB2207709.3A priority patent/GB2605894B/en
Priority to EP21723216.4A priority patent/EP4142725A1/en
Priority to CN202180043624.XA priority patent/CN115916200A/zh
Priority to EP21723215.6A priority patent/EP4142724A1/en
Priority to PCT/EP2021/061462 priority patent/WO2021219879A1/en
Priority to US17/922,072 priority patent/US20230202982A1/en
Priority to AU2021262514A priority patent/AU2021262514A1/en
Priority to US17/922,043 priority patent/US20230167064A1/en
Priority to PCT/EP2021/061464 priority patent/WO2021219881A1/en
Priority to KR1020227041920A priority patent/KR20230018386A/ko
Priority to CA3177000A priority patent/CA3177000A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB2006390.5A 2020-04-30 2020-04-30 Novel treatments Ceased GB202006390D0 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
GBGB2006390.5A GB202006390D0 (en) 2020-04-30 2020-04-30 Novel treatments
CA3177000A CA3177000A1 (en) 2020-04-30 2021-04-30 Novel compounds
EP21723216.4A EP4142725A1 (en) 2020-04-30 2021-04-30 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-quinoline-3-carboxamide potassium salt for treating inflammatory bowel diseases
EP21723215.6A EP4142724A1 (en) 2020-04-30 2021-04-30 Treatments of inflammatory bowel disease
AU2021266154A AU2021266154A1 (en) 2020-04-30 2021-04-30 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-quinoline-3-carboxamide potassium salt for treating inflammatory bowel diseases
CA3176994A CA3176994A1 (en) 2020-04-30 2021-04-30 Treatments of inflammatory bowel disease
JP2022566660A JP7702427B2 (ja) 2020-04-30 2021-04-30 炎症性腸疾患を治療するための５－クロロ－４－ヒドロキシ－１－メチル－２－オキソ－ｎ－フェニル－キノリン－３－カルボキサミドカリウム塩
CN202180044567.7A CN115768429B (zh) 2020-04-30 2021-04-30 用于治疗炎症性肠病的5-氯-4-羟基-1-甲基-2-氧代-n-苯基-喹啉-3-甲酰胺钾盐
GB2207709.3A GB2605894B (en) 2020-04-30 2021-04-30 Novel compounds
KR1020227041908A KR20230024892A (ko) 2020-04-30 2021-04-30 염증성 장 질환의 치료
CN202180043624.XA CN115916200A (zh) 2020-04-30 2021-04-30 炎症性肠病的治疗
JP2022566661A JP2023524519A (ja) 2020-04-30 2021-04-30 炎症性腸疾患の治療
PCT/EP2021/061462 WO2021219879A1 (en) 2020-04-30 2021-04-30 Treatments of inflammatory bowel disease
US17/922,072 US20230202982A1 (en) 2020-04-30 2021-04-30 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-quinoline-3-carboxamide potassium salt for treating inflammatory bowel diseases
AU2021262514A AU2021262514A1 (en) 2020-04-30 2021-04-30 Treatments of inflammatory bowel disease
US17/922,043 US20230167064A1 (en) 2020-04-30 2021-04-30 Treatments of inflammatory bowel disease
PCT/EP2021/061464 WO2021219881A1 (en) 2020-04-30 2021-04-30 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-quinoline-3-carboxamide potassium salt for treating inflammatory bowel diseases
KR1020227041920A KR20230018386A (ko) 2020-04-30 2021-04-30 염증성 장 질환 치료를 위한 5-클로로-4-히드록시-1-메틸-2-옥소-n-페닐-퀴놀린-3-카복사미드 칼륨 염

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2006390.5A GB202006390D0 (en) 2020-04-30 2020-04-30 Novel treatments

Publications (1)

Publication Number Publication Date
GB202006390D0 true GB202006390D0 (en) 2020-06-17

Family

ID=71080611

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB2006390.5A Ceased GB202006390D0 (en) 2020-04-30 2020-04-30 Novel treatments
GB2207709.3A Active GB2605894B (en) 2020-04-30 2021-04-30 Novel compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB2207709.3A Active GB2605894B (en) 2020-04-30 2021-04-30 Novel compounds

Country Status (9)

Country Link
US (2) US20230167064A1 (https=)
EP (2) EP4142725A1 (https=)
JP (2) JP7702427B2 (https=)
KR (2) KR20230018386A (https=)
CN (2) CN115768429B (https=)
AU (2) AU2021262514A1 (https=)
CA (2) CA3177000A1 (https=)
GB (2) GB202006390D0 (https=)
WO (2) WO2021219881A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202006390D0 (en) * 2020-04-30 2020-06-17 Aqilion Ab Novel treatments
CN115836056A (zh) * 2020-05-21 2023-03-21 Stemsynergy疗法有限责任公司 Notch抑制剂及其用途
CN115120727B (zh) * 2022-06-16 2024-02-23 甘肃农业大学 S100a9抑制剂在制备防治c型产气荚膜梭菌感染性腹泻药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
SE9400809D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of quinoline-3-carboxamide compounds
ES2393814T3 (es) * 2007-04-04 2012-12-28 Sigmoid Pharma Limited Una composición farmacéutica oral
PL2458992T3 (pl) * 2009-07-30 2016-07-29 Teva Pharma Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu
WO2012006538A1 (en) * 2010-07-09 2012-01-12 Teva Pharmaceutical Industries Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
EP2590653A4 (en) * 2010-07-09 2014-01-01 Teva Pharma 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROCHINOLINE-3-CARBOXAMIDE, SALT THEREOF AND APPLICATIONS THEREOF
WO2012050500A1 (en) 2010-10-14 2012-04-19 Lars Pettersson 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators.
US9200046B2 (en) * 2011-06-29 2015-12-01 Cornell University Reporter system for high throughput screening of compounds and uses thereof
GB202006390D0 (en) * 2020-04-30 2020-06-17 Aqilion Ab Novel treatments

Also Published As

Publication number Publication date
WO2021219881A1 (en) 2021-11-04
CA3176994A1 (en) 2021-11-04
CN115768429A (zh) 2023-03-07
AU2021262514A1 (en) 2023-01-05
JP2023524518A (ja) 2023-06-12
GB2605894A (en) 2022-10-19
CN115916200A (zh) 2023-04-04
JP7702427B2 (ja) 2025-07-03
CA3177000A1 (en) 2021-11-04
WO2021219879A1 (en) 2021-11-04
EP4142724A1 (en) 2023-03-08
US20230167064A1 (en) 2023-06-01
GB2605894B (en) 2023-06-14
KR20230024892A (ko) 2023-02-21
CN115768429B (zh) 2024-02-09
GB202207709D0 (en) 2022-07-06
KR20230018386A (ko) 2023-02-07
EP4142725A1 (en) 2023-03-08
AU2021266154A1 (en) 2023-01-05
US20230202982A1 (en) 2023-06-29
JP2023524519A (ja) 2023-06-12

Similar Documents

Publication Publication Date Title
GB202006390D0 (en) Novel treatments
GB202016058D0 (en) Therapeautic treatment
GB202003722D0 (en) Treatment
GB202018400D0 (en) Treatment
GB202116339D0 (en) Novel treatments
GB202112976D0 (en) Novel treatments
GB202112979D0 (en) Novel treatments
GB202112980D0 (en) Novel treatments
GB202112978D0 (en) Novel treatments
GB202112981D0 (en) Novel treatments
GB202112977D0 (en) Novel treatments
GB202109895D0 (en) Novel treatments
GB202109896D0 (en) Novel treatments
GB202109894D0 (en) Novel treatments
GB202103400D0 (en) Novel treatments
GB202101292D0 (en) Novel treatments
GB202101296D0 (en) Novel treatments
GB202101291D0 (en) Novel treatments
GB202017858D0 (en) Novel treatments
GB202010259D0 (en) Novel Treatments
GB202317035D0 (en) Novel treatments
GB202316907D0 (en) Novel treatments
GB202205069D0 (en) Novel treatments
GB202205070D0 (en) Novel treatments
GB202009086D0 (en) New treatments

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)